Elevai Labs Inc. Subsidiary, Elevai Skincare, Launches S-Series Root Renewal System, Marking Entry Into Hair Care Market
Elevai Labs Inc. Subsidiary, Elevai Skincare, Launches S-Series Root Renewal System, Marking Entry Into Hair Care Market
- Elevai Skincare Expands into Hair Care with Cutting-Edge Scalp and Hair Health System.
- Root Renewal System Features Exclusive Technologies and Science-Driven Formulations.
- Based on Over 15 Years of Research, 2 Pending Patents, as well as Clinical Studies Supported by Elevai Skincare and by Yuva Biosciences.
- Elevai护肤品进入护发领域,推出尖端头皮和头发健康系统。
- 根源修复系统采用独特技术和科学驱动的配方。
- 基于超过15年的研究、2项待决专利,以及Elevai护肤品和Yuva生物科学支持的临床研究。
NEWPORT BEACH, Calif., Dec. 06, 2024 (GLOBE NEWSWIRE) -- ELEVAI Labs Inc. (Nasdaq: ELAB) ("Elevai" or the "Company"), a diversified holding company, announces the launch of the S-Series Root Renewal System (the "Root Renewal System"), a revolutionary entry into the hair care market by its wholly owned subsidiary, Elevai Skincare Inc. ("Elevai Skincare"). The Root Renewal System is a three-part hair and scalp care system consisting of a shampoo, conditioner and serum that combines the latest in patent pending exosome and mitochondrial technology to target scalp and hair health at the cellular level.
加利福尼亚州纽波特海滩,2024年12月6日(环球新闻 wire)—— ELEVAI实验室公司(纳斯达克:ELAB)("Elevai"或"公司"),是一家多元化控股公司,宣布推出S系列根重生系统("根重生系统"),这是其全资子公司Elevai Skin care Inc.("Elevai Skin care")在护发市场的革命性切入点。根重生系统是一个三部分的头发和头皮护理系统,包括洗发水、护发素和精华,结合了最新的专利待审的外泌体和线粒体科技,旨在从细胞层面促进头皮和头发健康。
This launch reflects Elevai Skincare's ongoing commitment to science-driven, results-oriented innovations.
此次发布反映了Elevai护肤品对科学驱动、结果导向创新的持续承诺。
The Root Renewal System will be initially introduced through key medical aesthetics partners in select accounts across the United States. This phased rollout strategically positions the product as a premium offering ahead of the full launch, including e-commerce sales, in January 2025. Visit for more information.
根源再生系统将最初通过美国部分关键医疗美容合作伙伴引入。此分阶段的推广策略性地将该产品定位为一个高级产品,为2025年1月的全面发布,包括电子商务销售,做好准备。有关更多信息,请访问。
Exclusive Technologies and Groundbreaking Results
独家科技与突破性成果
The Root Renewal System incorporates two proprietary technologies that, when combined, offer unparalleled results for scalp and hair health:
根源再生系统结合了两项专有技术,当它们结合在一起时,可以为头皮和头发健康提供无与伦比的效果:
- Elevai PREx Exosomes: Nano-encapsulated growth factors protected by a lipid bilayer that support dormant hair follicles and overall scalp health.
- Y100 by Yuva Biosciences: An AI-discovered small molecule that supports mitochondrial function, which can result in increased cellular energy to rejuvenate hair follicles. BosleyMD has lauded the Y100 technology as "one of the biggest innovations in hair loss we've seen in twenty-five years," marking its first successful application in their new product line1.
- Elevai PREx外泌体:由脂质双层保护的纳米封装生长因子,支持休眠的毛囊和整体头皮健康。
- Yuva生物科学的Y100:一种由人工智能发现的小分子,支持线粒体功能,可能增加细胞能量以使毛囊复苏。BosleyMD称赞Y100技术为“我们在过去二十五年中看到的脱发领域最大的创新之一”,标志着其在新产品线中的首次成功应用。
"This system is a testament to our commitment to advancing the science of hair and scalp health," said Dr. Jordan R. Plews, Chief Executive Officer of Elevai Skincare. "By combining our proprietary PREx Exosomes with Yuva Bio's Y100 mitochondrial technology, we've developed a dual-mechanism solution that promotes follicle rejuvenation and scalp vitality. This groundbreaking synergy is backed by research and designed to deliver transformative results."
"该系统证明了我们致力于促进头发和头皮健康科学的承诺," Elevai Skincare的首席执行官乔丹·R·普卢斯博士表示。"通过将我们专有的PREx外泌体与Yuva Bio的Y100线粒体技术相结合,我们开发了一种双重机制解决方案,促进毛囊复兴和头皮活力。这一突破性协同效应得到了研究支持,并旨在提供变革性的效果。"
The Root Renewal System builds upon ongoing research conducted by Elevai Skincare in partnership with Carly Klein, President of National Hair Loss Medical Aesthetics. Previous studies demonstrated the effectiveness of Elevai's proprietary exosome technology in hair restoration, showing promising results in reversing hair thinning, reducing the signs of scalp inflammation, and promoting the recovery of dormant or miniaturized hair follicles.
根再生系统建立在Elevai Skincare与国家脱发医学美容协会主席卡莉·克莱因合作进行的持续研究基础上。先前的研究证明了Elevai的专有外泌体技术在头发修复中的有效性,显示出在逆转头发稀疏、减少头皮炎症迹象以及促进休眠或微型毛囊恢复方面的良好结果。
Positioned for Market Leadership
面向市场领导地位
"This launch marks a pivotal milestone for Elevai Skincare as its first new product launch since its current two and only products were launched in 2022, reflecting the strategic push for additional revenue streams under Elevai Labs' new leadership," said Graydon Bensler, Chief Executive Officer of Elevai Skincare parent company, Elevai Labs. "The Root Renewal System adds a breakthrough product to Elevai Skincare's portfolio, addressing growing demand in the high-growth hair care market. The Skincare sales team will be leveraging their strong relationships in the medical aesthetics space to position this product for early success, with a broader consumer rollout planned for January 2025. This launch not only strengthens Elevai Skincare's product offering but also creates significant new opportunities for growth and profitability."
"此次发布标志着Elevai Skincare的一个重大里程碑,因为自2022年以来推出的两款唯一产品后,这是其首个新产品发布,反映了Elevai Labs新领导下的战略推送,以获得额外的营业收入," Elevai Skincare母公司Elevai Labs的首席执行官格雷登·本斯勒表示。"根再生系统为Elevai Skincare的产品组合新增了一款突破性产品,满足头发护理市场快速增长的需求。Skincare销售团队将利用在医疗美容领域的强大关系,以确保该产品早期成功,计划于2025年1月进行更广泛的消费市场推广。此次发布不仅增强了Elevai Skincare的产品供给,也为增长和盈利创造了重大新机遇。"
About Elevai Labs, Inc.
关于Elevai Labs, Inc.
Elevai Labs Inc. (NASDAQ: ELAB) specializes in medical aesthetics and biopharmaceutical drug development, focusing on innovations for skin aesthetics and treatments tied to obesity and metabolic health. The Company operates a diverse portfolio of three wholly owned subsidiaries across the medical aesthetics and biopharmaceutical sectors, Elevai Skincare Inc., Elevai Biosciences Inc., and Elevai Research Inc. For more information please visit .
Elevai Labs Inc.(纳斯达克: ELAB)专注于医学美容和生物制药药物开发,致力于皮肤美学和与肥胖和代谢健康相关的治疗创新。该公司在医学美容和生物制药领域运营着三家全资子公司,分别是Elevai护肤品公司、Elevai生物科学公司和Elevai研究公司。欲了解更多信息,请访问 .
About Elevai Skincare Inc.
关于Elevai护肤公司。
A subsidiary of Elevai, Elevai Skincare is a medical aesthetics company developing and commercializing cutting-edge physician-dispensed skin and hair care applications that focuses on science-backed applications for the physician-dispensed market, utilizing cutting-edge technologies to redefine skincare and hair care, including its stem cell exosome technology. For more information, please visit elevaiskincare.com.
Elevai的子公司,Elevai Skincare是一家医疗美容公司,开发和商业化尖端的医生分发皮肤和头发护理应用,专注于以科学为基础的医生分发市场应用,利用尖端技术重新定义护肤和护发,包括其干细胞外泌体技术。有关更多信息,请访问elevaiskincare.com。
Forward-Looking Statements
前瞻性声明
Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Words such as "believes," "expects," "plans," "potential," "would" and "future" or similar expressions such as "look forward" are intended to identify forward-looking statements. Forward-looking statements are made as of the date of this press release and are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy, activities of regulators and future regulations and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results. Therefore, you should not rely on any of these forward-looking statements. These risks and uncertainties include, among others: Elevai's limited operating history and historical losses; Elevai's ability to raise additional funding to complete the development and any commercialization of its product candidates; Elevai's dependence on the success of its product candidates EL-22 and EL-32; that Elevai may be delayed in initiating, enrolling or completing any clinical trials; competition from third parties that are developing products for similar uses; Elevai's ability to obtain, maintain and protect its intellectual property; Elevai's dependence on third parties in connection with manufacturing, clinical trials and preclinical studies; and Elevai's expectations regarding its growth, strategy, progress and the design, objectives and timing of its studies. These and other risks are described more fully in Elevai's filings with the United States Securities and Exchange Commission ("SEC"), including the "Risk Factors" section of the Company's Annual Report on Form 10-K for the year ended December 31, 2023, filed with the SEC on March 29, 2024, and its other documents subsequently filed with or furnished to the SEC. Investors and security holders are urged to read these documents free of charge on the SEC's web site at www.sec.gov. All forward-looking statements contained in this press release speak only as of the date on which they were made. Except to the extent required by law, the Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.
本新闻稿中关于非历史事实事项的陈述是根据1995年修订的《私人证券诉讼改革法》所定义的“前瞻性陈述”。诸如“相信”、“期望”、“计划”、“潜在”、“将会”和“未来”或类似表达的词语,如“期待”,旨在识别前瞻性陈述。前瞻性陈述是截止本新闻稿日期时所做,并非历史事实或未来业绩的保证。相反,它们仅基于我们对业务未来、未来计划和策略、预测、预期事件和趋势、经济、监管机构活动及未来法规和其他未来条件的当前信念、期望和假设。由于前瞻性陈述与未来相关,因此它们受到固有的不确定性、风险和难以预测的情况变化的影响,其中许多因素在我们的控制之外。虽然公司相信这些前瞻性陈述中表达的期望是合理的,但无法保证这些期望最终会被证实是正确的,因此公司提醒投资者,实际结果可能与预期结果存在重大差异。因此,您不应依赖任何这些前瞻性陈述。这些风险和不确定性包括但不限于:Elevai的有限运营历史和历史亏损;Elevai为完成其产品候选者的开发和任何商业化所需额外资金的能力;Elevai对其产品候选者EL-22和EL-32成功的依赖;Elevai在启动、招募或完成任何临床试验方面可能会延迟;来自第三方的竞争,这些第三方正在开发相似用途的产品;Elevai获得、维护和保护其知识产权的能力;Elevai在制造、临床试验和临床前研究方面对第三方的依赖;以及Elevai对其增长、策略、进展及其研究的设计、目标和时间安排的预期。这些风险在Elevai向美国证券交易委员会(“SEC”)提交的文件中有更详细的描述,包括公司截至2023年12月31日的年度报告(Form 10-k)的“风险因素”部分,该报告于2024年3月29日提交给SEC,以及其随后提交或提供给SEC的其他文件。建议投资者和证券持有者免费查阅SEC网站上的这些文件。 www.sec.gov本新闻稿中包含的所有前瞻性陈述仅于其制作日期有效。除非法律要求,公司不承担更新此类陈述以反映其制作日期之后发生的事件或存在的情况的义务。
IR Contact:
IR@ElevaiLabs.com
IR联系方式:
IR@ElevaiLabs.com
1 "One of the Biggest Innovations in Hair Loss We've Seen in Twenty-Five Years" — BosleyMD Teams With Start-up Yuva Biosciences in National Launch of Breakthrough Technology | Business Wire
"在过去25年中,我们所见到的最大脱发创新之一" — BosleyMD与初创公司Yuva Biosciences合作,在全国推出突破性科技 | 业务电报